- Home
- M vs GRFS Comparison
M vs GRFS Comparison
Compare M & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | M | GRFS |
|---|---|---|
| Founded | 1830 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.4B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | M | GRFS |
|---|---|---|
| Price | $25.28 | $7.59 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 2 |
| Target Price | ★ $20.09 | $10.15 |
| AVG Volume (30 Days) | ★ 7.2M | 550.5K |
| Earning Date | 05-27-2026 | 07-28-2022 |
| Dividend Yield | ★ 3.97% | 1.80% |
| EPS Growth | ★ 12.08 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $22,621,000,000.00 | N/A |
| Revenue This Year | N/A | $4.49 |
| Revenue Next Year | N/A | $6.42 |
| P/E Ratio | $108.63 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.99 | $7.26 |
| 52 Week High | $25.65 | $11.14 |
Technical Indicators
Market Signals| Indicator | M | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 45.16 |
| Support Level | $16.74 | $7.44 |
| Resistance Level | N/A | $8.88 |
| Average True Range (ATR) | 1.09 | 0.17 |
| MACD | 0.32 | 0.01 |
| Stochastic Oscillator | 93.12 | 41.36 |
Price Performance
Historical ComparisonAbout M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.